NLS Acquisition

AstraZeneca has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD). AstraZeneca […]

In the end of November, Pfizer acquired Allergan for more than $150 billion, a deal which will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector, involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less […]

Getinge Group’s business area Infection Control, a global leader in infection control and contamination prevention solutions, has acquired Stericool, a Turkish company specializing in low temperature sterilization, and also signed an exclusive global distribution agreement with Canadian company TSO3 Inc., an innovator in sterilization technology for medical devices. The acquisition and distribution agreement are in […]

Pfizer has acquired Allergan for more than $150 billion, a deal that will create the world’s biggest drug maker. The deal, the largest ever in the healthcare sector and involves Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less than 10 percent of the […]

LEO Pharma and the Japanese pharmaceutical company Astellas Pharma have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.   Under the terms of the agreement, the assets and associated responsibilities relating to Astellas’ global portfolio of dermatology products – which include […]

CardiNor AS, a newly established Norwegian biotech company has received an initial USD 0,75 million to start development of an IVD for the neuropeptide Secretoneurin (SN). This neuropeptide is creating a great deal of interest as the potential missing link in  assessment and management of the 30 million patients having arrythmia. The new company’s management, […]